<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37332136</PMID><DateCompleted><Year>2023</Year><Month>08</Month><Day>17</Day></DateCompleted><DateRevised><Year>2023</Year><Month>08</Month><Day>18</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2163-8306</ISSN><JournalIssue CitedMedium="Internet"><Volume>12</Volume><Issue>8</Issue><PubDate><Year>2023</Year><Month>Aug</Month></PubDate></JournalIssue><Title>CPT: pharmacometrics &amp; systems pharmacology</Title><ISOAbbreviation>CPT Pharmacometrics Syst Pharmacol</ISOAbbreviation></Journal><ArticleTitle>Population pharmacokinetics of atacicept in systemic lupus erythematosus: An analysis of three clinical trials.</ArticleTitle><Pagination><StartPage>1157</StartPage><EndPage>1169</EndPage><MedlinePgn>1157-1169</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/psp4.12982</ELocationID><Abstract><AbstractText>B cell stimulating factor (BLyS) and a proliferation-inducing ligand (APRIL) are targets for novel treatments in patients with systemic lupus erythematosus (SLE). Atacicept is a recombinant, soluble fusion protein that blocks BLyS and APRIL activity. This study characterized the pharmacokinetic (PK) profile of atacicept using a population PK model and identified covariates explaining the PK variability. Total atacicept concentrations from a phase I study in healthy volunteers and two phase II studies in patients with SLE, using subcutaneous administration, were modeled using a quasi-steady-state approximation of the target-mediated drug disposition model with first-order absorption. The model included 3640 serum atacicept concentration records from 37 healthy volunteers and 503 patients with SLE and described total atacicept concentrations of the three trials, providing precise estimates of all parameters. Body weight and baseline BLyS concentration were the only statistically significant covariates, whereas no differences were found between patients and healthy volunteers. Apparent clearance and volume of the central compartment increased with body weight and initial target concentration increased with baseline BLyS. The change on atacicept exposure was moderate, with a difference in area under the curve compared with the median of 20%-32% for body weight, and 7%-18% for BLyS. Therefore, the effects of these covariates on atacicept exposure are not expected to be clinically relevant. The model described the complete total atacicept concentration-time profiles without finding any differences between healthy subjects and patients with SLE and supports the 150&#x2009;mg once weekly dose for further trials.</AbstractText><CopyrightInformation>&#xa9; 2023 Merck Institute for Pharmacometrics, Ares Trading S.A. CPT: Pharmacometrics &amp; Systems Pharmacology published by Wiley Periodicals LLC on behalf of American Society for Clinical Pharmacology and Therapeutics.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Pitsiu</LastName><ForeName>Maria</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Quantitative Pharmacology and Pharmacometrics, ICON Clinical Research UK Ltd, Marlow, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yalkinoglu</LastName><ForeName>&#xd6;zkan</ForeName><Initials>&#xd6;</Initials><AffiliationInfo><Affiliation>Translational Medicine, the healthcare business of Merck KGaA, Darmstadt, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Farrell</LastName><ForeName>Colm</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Quantitative Pharmacology and Pharmacometrics, ICON Clinical Research UK Ltd, Marlow, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Girard</LastName><ForeName>Pascal</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Merck Institute of Pharmacometrics, Lausanne, Switzerland, an Affiliate of Merck KGaA, Darmstadt, Germany, Ares Trading S.A., Lausanne, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vazquez-Mateo</LastName><ForeName>Cristina</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Global Clinical Development, EMD Serono, Billerica, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Papasouliotis</LastName><ForeName>Orestis</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Merck Institute of Pharmacometrics, Lausanne, Switzerland, an Affiliate of Merck KGaA, Darmstadt, Germany, Ares Trading S.A., Lausanne, Switzerland.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT00624338</AccessionNumber><AccessionNumber>NCT01972568</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D017426">Clinical Trial, Phase I</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>06</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>CPT Pharmacometrics Syst Pharmacol</MedlineTA><NlmUniqueID>101580011</NlmUniqueID><ISSNLinking>2163-8306</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>K3D9A0ICQ3</RegistryNumber><NameOfSubstance UI="C524618">TACI receptor-IgG Fc fragment fusion protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011993">Recombinant Fusion Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011993" MajorTopicYN="N">Recombinant Fusion Proteins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>M.P. and C.F. are employees of ICON Clinical Research UK Ltd, Marlow, UK; ICON received professional fees for performing the analysis. &#xd6;.Y. was an employee of the healthcare business of Merck KGaA, Darmstadt, Germany, when the study was conducted. P.G. and O.P. are employees of Merck Institute for Pharmacometrics, Lausanne, Switzerland, an affiliate of Merck KGaA, Darmstadt, Germany. C.V.&#x2010;M. is an employee of EMD Serono, Billerica, MA, USA.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>4</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>8</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>4</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>8</Month><Day>17</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>6</Month><Day>19</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>6</Month><Day>19</Day><Hour>0</Hour><Minute>33</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37332136</ArticleId><ArticleId IdType="pmc">PMC10431037</ArticleId><ArticleId IdType="doi">10.1002/psp4.12982</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Lisnevskaia L, Murphy G, Isenberg D. Systemic lupus erythematosus. Lancet. 2014;384:1878&#x2010;1888.</Citation><ArticleIdList><ArticleId IdType="pubmed">24881804</ArticleId></ArticleIdList></Reference><Reference><Citation>Pan L, Lu MP, Wang JH, Xu M, Yang SR. Immunological pathogenesis and treatment of systemic lupus erythematosus. World J Pediatr. 2020;16:19&#x2010;30.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7040062</ArticleId><ArticleId IdType="pubmed">30796732</ArticleId></ArticleIdList></Reference><Reference><Citation>Murphy G, Isenberg DA. Biologic therapies for systemic lupus erythematosus: where are we now? Curr Opin Rheumatol. 2020;32:597&#x2010;608.</Citation><ArticleIdList><ArticleId IdType="pubmed">32890026</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu T, Enioutina EY, Brunner HI, Vinks AA, Sherwin CM. Clinical pharmacokinetics and pharmacodynamics of biologic therapeutics for treatment of systemic lupus erythematosus. Clin Pharmacokinet. 2017;56:107&#x2010;125.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5575762</ArticleId><ArticleId IdType="pubmed">27384528</ArticleId></ArticleIdList></Reference><Reference><Citation>Bluml S, McKeever K, Ettinger R, Smolen J, Herbst R. B&#x2010;cell targeted therapeutics in clinical development. Arthritis Res Ther. 2013;15 Suppl 1:S4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3624127</ArticleId><ArticleId IdType="pubmed">23566679</ArticleId></ArticleIdList></Reference><Reference><Citation>Roschke V, Sosnovtseva S, Ward CD, et al. BLyS and APRIL form biologically active heterotrimers that are expressed in patients with systemic immune&#x2010;based rheumatic diseases. J Immunol. 2002;169:4314&#x2010;4321.</Citation><ArticleIdList><ArticleId IdType="pubmed">12370363</ArticleId></ArticleIdList></Reference><Reference><Citation>Parodis I, Stockfelt M, Sj&#xf6;wall C. B cell therapy in systemic lupus erythematosus: from rationale to clinical practice. Front Med (Lausanne). 2020;7:316.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7381321</ArticleId><ArticleId IdType="pubmed">32754605</ArticleId></ArticleIdList></Reference><Reference><Citation>Furie R, Petri M, Zamani O, et al. A phase III, randomized, placebo&#x2010;controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum. 2011;63:3918&#x2010;3930.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5007058</ArticleId><ArticleId IdType="pubmed">22127708</ArticleId></ArticleIdList></Reference><Reference><Citation>Morand EF, Furie R, Tanaka Y, et al. Trial of anifrolumab in active systemic lupus erythematosus. N Engl J Med. 2020;382:211&#x2010;221.</Citation><ArticleIdList><ArticleId IdType="pubmed">31851795</ArticleId></ArticleIdList></Reference><Reference><Citation>Navarra SV, Guzm&#xe1;n RM, Gallacher AE, et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo&#x2010;controlled, phase 3 trial. Lancet. 2011;377:721&#x2010;731.</Citation><ArticleIdList><ArticleId IdType="pubmed">21296403</ArticleId></ArticleIdList></Reference><Reference><Citation>Dillon SR, Harder B, Lewis KB, et al. B&#x2010;lymphocyte stimulator/a proliferation&#x2010;inducing ligand heterotrimers are elevated in the sera of patients with autoimmune disease and are neutralized by atacicept and B&#x2010;cell maturation antigen&#x2010;immunoglobulin. Arthritis Res Ther. 2010;12:R48.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2888197</ArticleId><ArticleId IdType="pubmed">20302641</ArticleId></ArticleIdList></Reference><Reference><Citation>Isenberg D, Gordon C, Licu D, Copt S, Rossi CP, Wofsy D. Efficacy and safety of atacicept for prevention of flares in patients with moderate&#x2010;to&#x2010;severe systemic lupus erythematosus (SLE): 52&#x2010;week data (APRIL&#x2010;SLE randomised trial). Ann Rheum Dis. 2015;74:2006&#x2010;2015.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4680140</ArticleId><ArticleId IdType="pubmed">24951103</ArticleId></ArticleIdList></Reference><Reference><Citation>Merrill JT, Wallace DJ, Wax S, et al. Efficacy and safety of atacicept in patients with systemic lupus erythematosus. Arthritis Rheumatol. 2018;70:266&#x2010;276.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6099253</ArticleId><ArticleId IdType="pubmed">29073347</ArticleId></ArticleIdList></Reference><Reference><Citation>Willen D, Uhl W, Wolna P, Papasouliotis O, Yalkinoglu &#xd6;. Safety, tolerability, pharmacokinetics, and pharmacodynamics of atacicept in a randomized trial in healthy Caucasian and Japanese subjects. Eur J Drug Metab Pharmacokinet. 2020;45:27&#x2010;40.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6994531</ArticleId><ArticleId IdType="pubmed">31529406</ArticleId></ArticleIdList></Reference><Reference><Citation>Wallace DJ, Isenberg DA, Morand EF, et al. Safety and clinical activity of atacicept in the long&#x2010;term extension of the phase IIb ADDRESS II study in systemic lupus erythematosus. Rheumatology. 2021;60:5379&#x2010;5389.</Citation><ArticleIdList><ArticleId IdType="pubmed">33547784</ArticleId></ArticleIdList></Reference><Reference><Citation>Morand E, Isenberg DA, Wallace DJ, et al. Attainment of treat&#x2010;to&#x2010;target endpoints in SLE patients with high disease activity in the atacicept phase 2b ADDRESS II study. Rheumatology (Oxford). 2020;59:2930&#x2010;2938.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7516108</ArticleId><ArticleId IdType="pubmed">32107560</ArticleId></ArticleIdList></Reference><Reference><Citation>Beal SL, Sheiner LB, Boeckmann A, Bauer RJ. NONMEM user's guides. (1989&#x2013;2015) 7.3.0 edition. Icon Development Solutions; 2013.</Citation></Reference><Reference><Citation>Wang Y. Derivation of various NONMEM estimation methods. J Pharmacokinet Pharmacodyn. 2007;34:575&#x2010;593.</Citation><ArticleIdList><ArticleId IdType="pubmed">17620001</ArticleId></ArticleIdList></Reference><Reference><Citation>Mould DR, Upton RN. Basic concepts in population modeling, simulation, and model&#x2010;based drug development &#x2013; part 2: introduction to pharmacokinetic modeling methods. CPT Pharmacometrics Syst Pharmacol. 2013;2:e38.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3636497</ArticleId><ArticleId IdType="pubmed">23887688</ArticleId></ArticleIdList></Reference><Reference><Citation>Mager DE, Jusko WJ. General pharmacokinetic model for drugs exhibiting target&#x2010;mediated drug disposition. J Pharmacokinet Pharmacodyn. 2001;28:507&#x2010;532.</Citation><ArticleIdList><ArticleId IdType="pubmed">11999290</ArticleId></ArticleIdList></Reference><Reference><Citation>Gibiansky L, Gibiansky E, Kakkar T, Ma P. Approximations of the target&#x2010;mediated drug disposition model and identifiability of model parameters. J Pharmacokinet Pharmacodyn. 2008;35:573&#x2010;591.</Citation><ArticleIdList><ArticleId IdType="pubmed">19005743</ArticleId></ArticleIdList></Reference><Reference><Citation>Papasouliotis O, Yalkinoglu &#xd6;, Golob M, Willen D, Girard P. Population pharmacokinetics of atacicept in systemic lupus erythematosus (SLE). Ann Rheum Dis. 2015;74(Suppl 2):1077.</Citation></Reference><Reference><Citation>Yano Y, Beal SL, Sheiner LB. Evaluating pharmacokinetic/pharmacodynamic models using the posterior predictive check. J Pharmacokinet Pharmacodyn. 2001;28:171&#x2010;192.</Citation><ArticleIdList><ArticleId IdType="pubmed">11381569</ArticleId></ArticleIdList></Reference><Reference><Citation>Munafo A, Priestley A, Nestorov I, Visich J, Rogge M. Safety, pharmacokinetics and pharmacodynamics of atacicept in healthy volunteers. Eur J Clin Pharmacol. 2007;63:647&#x2010;656.</Citation><ArticleIdList><ArticleId IdType="pubmed">17473917</ArticleId></ArticleIdList></Reference><Reference><Citation>Dall'Era M, Chakravarty E, Wallace D, et al. Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus: results of a multicenter, phase Ib, double&#x2010;blind, placebo&#x2010;controlled, dose&#x2010;escalating trial. Arthritis Rheum. 2007;56:4142&#x2010;4150.</Citation><ArticleIdList><ArticleId IdType="pubmed">18050206</ArticleId></ArticleIdList></Reference><Reference><Citation>Nestorov I, Papasouliotis O, Pena Rossi C, Munafo A. Pharmacokinetics and immunoglobulin response of subcutaneous and intravenous atacicept in patients with systemic lupus erythematosus. J Pharm Sci. 2010;99:524&#x2010;538.</Citation><ArticleIdList><ArticleId IdType="pubmed">19743503</ArticleId></ArticleIdList></Reference><Reference><Citation>Pena&#x2010;Rossi C, Nasonov E, Stanislav M, et al. An exploratory dose&#x2010;escalating study investigating the safety, tolerability, pharmacokinetics and pharmacodynamics of intravenous atacicept in patients with systemic lupus erythematosus. Lupus. 2009;18:547&#x2010;555.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3835146</ArticleId><ArticleId IdType="pubmed">19395457</ArticleId></ArticleIdList></Reference><Reference><Citation>Nestorov I, Munafo A, Papasouliotis O, Visich J. Pharmacokinetics and biological activity of atacicept in patients with rheumatoid arthritis. J Clin Pharmacol. 2008;48:406&#x2010;417.</Citation><ArticleIdList><ArticleId IdType="pubmed">18303125</ArticleId></ArticleIdList></Reference><Reference><Citation>Ansell SM, Witzig TE, Inwards DJ, et al. Phase I clinical study of atacicept in patients with relapsed and refractory B&#x2010;cell non&#x2010;Hodgkin's lymphoma. Clin Cancer Res. 2008;14:1105&#x2010;1110.</Citation><ArticleIdList><ArticleId IdType="pubmed">18281543</ArticleId></ArticleIdList></Reference><Reference><Citation>Rossi JF, Moreaux J, Hose D, et al. Atacicept in relapsed/refractory multiple myeloma or active Waldenstrom's macroglobulinemia: a phase I study. Br J Cancer. 2009;101:1051&#x2010;1058.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2768101</ArticleId><ArticleId IdType="pubmed">19789533</ArticleId></ArticleIdList></Reference><Reference><Citation>Eslami M, Willen D, Papasouliotis O, et al. Kinetics of free and ligand&#x2010;bound atacicept in human serum. Front Immunol. 2022;13:1035556.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9756848</ArticleId><ArticleId IdType="pubmed">36532058</ArticleId></ArticleIdList></Reference><Reference><Citation>Dasgupta A. Usefulness of monitoring free (unbound) concentrations of therapeutic drugs in patient management. Clin Chim Acta. 2007;377:1&#x2010;13.</Citation><ArticleIdList><ArticleId IdType="pubmed">17026974</ArticleId></ArticleIdList></Reference><Reference><Citation>Kowalczyk&#x2010;Quintas C, Willen D, Willen L, et al. No interactions between heparin and atacicept, an antagonist of B cell survival cytokines. Br J Pharmacol. 2019;176:4019&#x2010;4033.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6811742</ArticleId><ArticleId IdType="pubmed">31355456</ArticleId></ArticleIdList></Reference><Reference><Citation>
Papasouliotis O, Yalkinolglu O, Vazquez&#x2010;Mateo C, et al. Exposure&#x2010;response modelling and exposure&#x2010;safety modelling analyses in two phase II studies of atacicept in SLE. Arthritis Rheumatol. 2017;69(Suppl 10). Accessed May 19, 2023. https://acrabstracts.org/abstract/exposure&#x2010;response&#x2010;modelling&#x2010;and&#x2010;exposure&#x2010;safety&#x2010;modelling&#x2010;&#x2010;analyses&#x2010;in&#x2010;two&#x2010;phase&#x2010;ii&#x2010;studies&#x2010;of&#x2010;atacicept&#x2010;in&#x2010;sle/
</Citation></Reference><Reference><Citation>Wallace DJ, Stohl W, Furie RA, et al. A phase II, randomized, double&#x2010;blind, placebo&#x2010;controlled, dose&#x2010;ranging study of belimumab in patients with active systemic lupus erythematosus. Arthritis Rheum. 2009;61:1168&#x2010;1178.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2758229</ArticleId><ArticleId IdType="pubmed">19714604</ArticleId></ArticleIdList></Reference><Reference><Citation>Cogollo E, Silva MA, Isenberg D. Profile of atacicept and its potential in the treatment of systemic lupus erythematosus. Drug Des Devel Ther. 2015;9:1331&#x2010;1339.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4357613</ArticleId><ArticleId IdType="pubmed">25834391</ArticleId></ArticleIdList></Reference><Reference><Citation>Furie RA, Leon G, Thomas M, et al. A phase 2, randomised, placebo&#x2010;controlled clinical trial of blisibimod, an inhibitor of B cell activating factor, in patients with moderate&#x2010;to&#x2010;severe systemic lupus erythematosus, the PEARL&#x2010;SC study. Ann Rheum Dis. 2015;74:1667&#x2010;1675.</Citation><ArticleIdList><ArticleId IdType="pubmed">24748629</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>